LXW7

LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect[1][2][3].

Product Specifications

CAS Number

[1313004-77-1]

UNSPSC

12352209

Hazard Statement

H302, H315, H319

Target

Integrin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/lxw7.html

Purity

99.02

Solubility

H2O

Smiles

O=C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@H](CC(O)=O)C(N[C@@H]1C(C)C)=O)=O)=O)=O)=O)[C@@H](CSSC[C@H](C(N)=O)NC1=O)N

Molecular Formula

C29H48N12O12S2

Molecular Weight

820.89

Precautions

H302, H315, H319

References & Citations

[1]Xiao W, et al. The use of one-bead one-compound combinatorial library technology to discover high-affinity αvβ3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol Cancer Ther. 2010 Oct;9 (10) :2714-23.|[2]Fang T, et al. LXW7 ameliorates focal cerebral ischemia injury and attenuates inflammatory responses in activated microglia in rats. Braz J Med Biol Res. 2016 Aug 1;49 (9) :e5287.|[3]Hao D, et al. Discovery and Characterization of a Potent and Specific Peptide Ligand Targeting Endothelial Progenitor Cells and Endothelial Cells for Tissue Regeneration. ACS Chem Biol. 2017 Apr 21;12 (4) :1075-1086.